Flomax ulcerative colitis

Ulcerative Colitis. Crohn’s Disease. Stem cell therapy and Viagra dose 25 mg viagra soft tabs 50mg flomax generic over the counter viagra 25 mg yeterli cheap viagra 25mg cheap viagra 100mg tablets viagra dosage 25 or 50. Remission in patients with nonspecific ulcerative colitis lasts, on the average, for 12–15 months, and in patients with Crohn’s disease – for up to 2.5–3 years.

FDA Approved Drugs in Family Medicine CenterWatch Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016 Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of mraine, Approved January 2016 Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately controlled type II diabetes, Approved November 2016 Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo isk; For the treatment of inadequately controlled type II diabetes, Approved November 2016 Cosentyx (secukinumab); Novartis; For the treatment of plaque psoriasis, Approved January 2015 Cresemba (isavuconazonium sulfate) ; Astellas; For the treatment of invasive aspergillosis and invasive mucormycosis, Approved March 2015 Enstilar (calcipotriene and betamethasone dipropionate); LEO Pharmaceuticals; For the treatment of psoriasis, Approved October 2015 Kybella (deoxycholic acid); Kythera Biopharma; For the treatment of submental fat, Approved April 2015 Otiprio (ciprofloxacin otic suspension); Otonomy; For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement, Approved December 2015 Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015 Viberzi (eluxadoline); Actavis; For the treatment of irritable bowel syndrome with diarrhea, Approved May 2015 Xifaxan (rifaximin); Salix Pharmaceuticals; For the treatment of irritable bowel syndrome with diarrhea , Approved May 2015 Afrezza (insulin human) Inhalation Powder; Mannkind; For the treatment of diabetes mellitus, Approved June 2014 Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec; For the treatment of hemophilia B, Approved March 2014 Arnuity Ellipta (fluticasone furoate inhalation powder); Glaxo Smith Kline; For the treatment of asthma, Approved August 2014 Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals; For the treatment of hypogonadism, Approved March 2014 Belsomra (suvorexant); Merck; For the treatment of insomnia, Approved August 2014 Bunavail (buprenorphine and naloxone); Bio Delivery Sciences; For the maintenance treatment of opioid dependence, Approved June 2014 Contrave (naltrexone HCl and bupropion HCl) ; Takeda Pharmaceuticals U. A.; For chronic weht management , Approved September 2014 Dalvance (dalbavancin); Durata Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved May 2014 Dyloject (diclofenac sodium) Injection; Hospira; For the management of mild, moderate or severe pain, Approved December 2014 Entyvio (vedolizumab); Millenium Pharmaceuticals; For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014 Farxa (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014 Grastek (Timothy Grass Pollen Allergen Extract); Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014 Jardiance (empagliflozin) ; Boehringer Ingelheim; For the treatment of type II diabetes, Approved August 2014 Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014 Metronidazole 1.3% Vaginal Gel; Actavis, Inc.; For the treatment of bacterial vaginosis, Approved April 2014 Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014 Natesto, (testosterone) nasal gel; Trimel Pharmaceuticals; For the treatment of deficiency or absence of endogenous testosterone, Approved May 2014 Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014 Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014 Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014 Otezla (apremilast); Celgene; For the treatment of moderate to severe plaque psoriasis, Approved September 2014 Plegridy (peginterferon beta-1a); Biogen IDEC.; For the treatment of relapsing multiple sclerosis, Approved August 2014 Qudexy XR (topiramate); Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014 Ragwitek (Short Ragweed Pollen Allergen Extract); Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014 Rapivab (peramivir injection); Biocryst; For the treatment of acute uncomplicated influenza in adults, Approved December 2014 Saxenda (liraglutide [r DNA orin] injection); Novo isk; For chronic weht management, Approved December 2014 Tanzeum (alblutide); Glaxo Smith Kline; For the treatment of type II diabetes mellitus, Approved April 2014 Targiniq ER (oxycodone hydrocoride naloxone hydrocoride) extended-release tablets; Purdue Pharma; For the management of severe chronic pain, Approved July 2014 Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014 Trulicity (dulaglutide); Eli Lilly; To improve glycemic control in type II diabetics, Approved September 2014 Xartemis XR (oxycodone hydrocoride and acetaminophen) extended release; Mallinckrodt Pharmaceuticals; For the management of acute pain, Approved March 2014 Xtoro (finafloxacin otic suspension) 0.3%; Alcon; For the treatment of acute otitis externa, Approved December 2014 Zerbaxa (ceftolozane tazobactam) ; Cubist Pharmaceuticals; For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014 Actemra (ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013 Anoro Ellipta (umeclidinium and vilanterol inhalation powder); Glaxo Smith Kline; For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013 Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); Glaxo Smith Kline; For the treatment of chronic obstructive pulmonary disease, Approved May 2013 Diclegis (doxylamine succinate pyridoxine hydrocoride DR tablets); Duchesnay USA; For the treatment of nausea and vomiting of pregnancy, Approved April 2013 Duavee (conjugated estrogens/bazedoxifene); Pfizer; For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013 Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013 Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013 Invokana (canagliflozin); Janssen Pharmaceuticals; For the treatment of type II diabetes mellitus, Approved April 2013 Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyoerlipidemia, Approved May 2013 Nesina (alogliptin); Takeda; For the treatment of type II diabetes mellitus, Approved January 2013 Olysio (simeprevir); Janssen Therapeutics; For the treatment of hepatitis C, November of 2013 Osphena (ospemifene); Shionogi; For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013 Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol); Teva Pharmaceutical; For the prevention of conception, Approved April 2013 Sitav (acyclovir) buccal tablets; Bio Alliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013 Sovaldi (sofosbuvir); Gilead Sciences; For the treatment of hepatitis C, December of 2013 Tecfidera (dimethyl fumarate); Biogen Idec; For the treatment of relapsing multiple sclerosis, Approved March 2013 Uceris (budesonide); Santarus; For the treatment of ulcerative colitis, Approved January 2013 Xiaflex (collagenase clostridium histolyticum); Auxilium; For the treatment of Peyronie's disease, Approved December of 2013 Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene; For the treatment of non-small cell lung cancer, Approved October 2012 Afinitor (everolimus); Novartis; For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012 Afinitor (everolimus); Novartis; For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012 Aubagio (teriflunomide); Sanofi Aventis; For the treatment of multiple sclerosis, Approved September 2012 Bydureon (exenatide extended-release for injectable suspension); Amylin; For the improvement of glycemic control in adults with type II diabetes mellitus, Approved January 2012 Cometriq (cabozantinib); Exelixis; For the treatment of metastatic medullary thyroid cancer, Approved November 2012 Cystaran (cysteamine hydrocoride); Sma Tau Pharmaceuticals; For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012 Dymista (azelastine hydrocoride and fluticasone propionate); Meda Pharmaceuticals Inc; For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012 Elelyso (tallucerase alfa); Pfizer; For the treatment of Gaucher disease, Approved May 2012 Erivedge (vismodegib); Genentech; For the treatment of basal cell carcinoma, Approved January 2012 Fycompa (perampanel); Eisai; For the treatment of partial-onset seizures with or without secondarily generalized seizures, Approved October 2012 Horizant (gabapentin enacarbil); Glaxo Smith Kline; For the treatment of postherpetic neuralgia, Approved June 2012 Inlyta (axitinib); Pfizer; For the treatment of advanced renal cell carcinoma, Approved January 2012 Jentadueto (linagliptin plus metformin hydrocoride); Eli Lilly; For the treatment of type II diabetes, Approved February 2012 Jetrea (ocriplasmin); Thrombogenics; For the treatment of symptomatic vitreomacular adhesion, Approved October 2012 Korlym (mifepristone); Corcept Therapeutics; For the control of hyperglycemia in adults with endogenous Cushing’s syndrome, Approved February 2012 Kyprolis (carfilzomib); Onyx Pharmaceuticals; For the treatment of multiple myeloma, Approved July 2012 Linzess (linaclotide); Forest Labs and Ironwood Pharmaceuticals; For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012 Lucentis (ranibizumab injection); Genentech; For the treatment of diabetic macular edema, Approved August 2012 Lyrica (pregabalin); Pfizer; For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012 Myrbetriq (mirabegron); Astellas Pharma US, Inc; For the treatment of overactive bladder, Approved June 2012 Natazia (estradiol valerate and estradiol valerate/dienogest); Bayer; For the treatment of heavy menstrual bleeding, Approved March 2012 Neupro (Rototine Transdermal System); UCB; For the treatment of Restless Legs Syndrome, Approved April 2012 Omontys (peginesatide); Affymax; For the treatment of anemia due to chronic kidney disease, Approved March 2012 Oxtellar XR (oxcarbazepine extended release); Supernus Pharmaceuticals; For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age, Approved October 2012 Perjeta (pertuzumab); Genentech; For the first-line treatment of HER2 metastatic breast cancer, Approved June 2012 Picato (ingenol mebutate) gel; LEO Pharma; For the treatment of actinic keratosis, Approved January 2012 Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical; For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012 Quillivant XR (methylphenidate hydrocoride); Next Wave Pharmaceuticals; For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012 Rayos (prednisone) delayed-release tablets; Horizon Pharma; For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions, Approved July of 2012 Sklice (ivermectin) lotion; Sanofi Pasteur; For the treatment of head lice, Approved February 2012 Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012 Stivarga (regorafenib); Bayer Health Care Pharmaceuticals; For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012 Stribild (elvitegravir, cobicistat, ericitabine, tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 infection, Approved August 2012 Subsys (fentanyl sublingual spray); Insys Therapeutics; For the treatment of breakthrough cancer pain, Approved January of 2012 Surfaxin (lucinactant); Discovery Laboratories; For the treatment of respiratory distress syndrome in premature infants, Approved March 2012 Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories; For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012 Viokace (pancrelipase) tablets; Aptalis Pharma; For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012 Voraxaze (glucarpidase); BTG International; For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function, Approved January 2012 Xeljanz (tofacitinib); Pfizer; For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012 Xtandi (enzalutamide); Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012 Zaltrap (ziv-aflibercept); Sanofi-aventis; For the treatment of metastatic colorectal cancer, Approved August 2012 Zioptan (tafluprost ophthalmic solution); Merck; For the treatment of elevated intraocular pressure, Approved February 2012 Abstral (fentanyl sublingual tablets); Pro Strakan; For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011 Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011 Anturol (oxybutynin) Gel; Antares Pharma; For the treatment of overactive bladder, Approved December 2011 Arcapta (indacaterol maleate inhalation powder); Novartis; For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease, Approved July 2011 Benlysta (belimumab); Human Genome Sciences; For the treatment of systemic lupus erythematosus, Approved March 2011 Complera (ericitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011 Daliresp (roflumilast); Forest Pharmaceuticals; For the treatment of chronic obstructive pulmonary disease, Approved February 2011 Dificid (fidaxomicin); Optimer Pharmaceuticals; For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011 Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011 Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011 Edarbyclor (azilsartan medoxomil and corthalidone); Takeda; For the treatment of hypertension, Approved December of 2011 Edurant (rilpivirine); Tibotec; For the treatment of HIV-1, Approved May 2011 Exparel (bupivacaine liposome injectable suspension); Pacira Pharmaceuticals; For postsurgical analgesia, Approved November 2011 Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011 Ferriprox (deferiprone); Apotex; For the treatment of transfusional iron overload due to thalassemia, Approved October 2011 Firazyr (icatibant); Shire Pharmaceuticals; For the treatment of acute attacks of hereditary angioedema, Approved August of 2011 Gralise (gabapentin); Abbott Laboratories; For the treatment of postherpetic neuralgia, Approved February 2011 Horizant (gabapentin enacarbil); Glaxo Smith Kline; For the treatment of restless legs syndrome, Approved April 2011 Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals; For the treatment of insomnia, Approved November 2011 Juvisync (sitagliptin and simvastatin); Merck; For the treatment of type II diabetes, Approved October 2011 Lazanda (fentanyl citrate) nasal spray; Archimedes; For the management of breakthrough cancer pain, Approved June 2011 Makena (hydroxyprogesterone caproate injection); Hologic; For the prevention of risk of preterm birth, Approved February 2011 Nulojix (belatacept); Bristol-Myers Squibb; For the prevention of organ rejection following kidney transplant, Approved June 2011 Onfi (clobazam); Lundbeck; For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Approved October 2011 Oxecta (oxycodone HCl); Pfizer; For the management of acute and chronic moderate to severe pain, Approved June 2011 Pota (ezogabine); Valeant Pharmaceuticals; For the treatment of partial-onset seizures, Approved June 2011 Soliris (eculizumab); Alexion; For the treatment of atypical hemolytic uremic syndrome, Approved September 2011 Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011 Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011 Tradjenta (linagliptin); Boehringer Ingelheim; For the treatment of type II diabetes, Approved May 2011 Vandetanib (vandetanib); Astra Zeneca; For the treatment of thyroid cancer, Approved April 2011 Viibryd (vilazodone hydrocoride); Clinical Data; For the treatment of major depressive disorder, Approved January 2011 Xalkori (crizotinib); Pfizer; For the treatment of ALK non-small cell lung cancer, Approved August of 2011 Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011 Xarelto (rivaroxaban); Janssen Pharmaceuticals; For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011 Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011 Zelboraf (vemurafenib); Roche; For the treatment of BRAF melanoma, Approved August of 2011 Zyta (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011 Actemra (tocilizumab); Genentech; For the treatment of rheumatoid arthritis, Approved January 2010 Ampyra (dalfampridine); Acorda; For the improvement of walking in patients with multiple sclerosis, Approved January 2010 Aurnide (aliskiren amlodipine hydrocorothiazide); Novartis; For the treatment of uncontrolled hypertension, Approved December 2010 Botox (onabotulinuoxin A); Allergan; For the treatment of chronic mraine, Approved October 2010 Botox (onabotulinuoxin A); Allergan; For the treatment of upper limb spasticity, Approved March 2010 Butrans (buprenorphine) Transdermal System; Purdue Pharma; moderate to severe chronic pain, Approved July 2010 Cuvposa (glycopyrrolate); Shionogi; For the treatment of chronic severe drooling in pediatrics with neurologic conditions, Approved July 2010 Dulera (mometasone furoate formoterol fumarate dihydrate); Merck; For the treatment of asthma, Approved June 2010 Egrifta (tesamorelin for injection); Theratechnologies; For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010 Exalgo (hydromorphone hydrocoride) extended release; Alza; For the management of moderate to severe pain, Approved March 2010 Gilenya (fingolimod); Novartis; For the treatment of relapsing multiple sclerosis, Approved September 2010 Halaven (eribulin mesylate); Eisai; For the treatment of metastatic breast cancer, Approved November 2010 Herceptin (trastuzumab); Genentech; For the treatment of gastric cancer, Approved October 2010 Jalyn (dutasteride tamsulosin); Glaxo Smith Kline; For the treatment of benn prostatic hyperplasia, Approved June 2010 Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010 Kapvay (clonidine hydrocoride); Shionogi; For the treatment of attention deficit hyperactivity disorder, Approved October 2010 Krystexxa (pegloticase); Savient Pharma; For the treatment of chronic gout (hyperuricemia), Approved September 2010 Oleptro (trazodone hydrocoride); Labopharm; For the treatment of major depressive disorder, Approved February 2010 Pradaxa (dabatran etexilate mesylate); Boehringer Ingelheim; For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010 Prolia (denosumab); Amgen; For the treatment of postmenopausal women with osteoporosis at hh risk for fracture, Approved June 2010 Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010 Silenor (doxepin); Somaxon Pharma; For the treatment of insomnia, Approved March 2010 Sprix (ketorolac tromethamine); Roxro Pharma; For the treatment of moderate to severe pain, Approved May 2010 Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010 Tekamlo (aliskiren amlodipine); Novartis; For the treatment of hypertension, Approved August 2010 Tribenzor (olmesartan medoxomil amlodipine hydrocorothiazide); Daiichi Sankyo; For the treatment of hypertension, Approved July 2010 Veltin (clindamycin phosphate and tretinoin); Stiefel; For the treatment of acne vulgaris, Approved July 2010 Victoza (liraglutide); Novo isk; For the treatment of type 2 diabetes mellitus, Approved January 2010 Vimovo (naproxen esomeprazole); Astra Zeneca; For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010 Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the prevention of relapse to opioid dependence, Approved October 2010 Zymaxid (gatifloxacin ophthalmic solution); Allergan; For the treatment of bacterial conjunctivitis, Approved May 2010 Adcirca (tadalafil); Eli Lilly; For the treatment of pulmonary arterial hypertension, Approved May 2009 Afinitor (everolimus); Novartis; For the treatment of renal cell carcinoma, Approved March 2009 Avastin (bevacizumab); Genentech; For the treatment of renal cell carcinoma, Approved July 2009 Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009 Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals; For the treatment of mraine attacks, Approved June of 2009 Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; Glaxo Smith Kline; For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009 Cimzia (certolizumab pegol); UCB; For the treatment of rheumatoid arthritis, Approved May of 2009 Cycloset, bromocriptine mesylate; Vero Science; For the treatment of type 2 diabetes mellitus, Approved May 2009 Embeda (morphine sulfate and naltrexone hydrocoride); King Pharmaceuticals; For the treatment of moderate to severe pain, Approved August of 2009 Extavia (Interferon beta-l b); Novartis; For the treatment of relapsing multiple sclerosis, Approved August of 2009 Intuniv (guanfacine extended-release); Shire Pharmaceuticals; For the treatment of ADHD in children and adolescents, Approved September 2009 Metozolv ODT (metoclopramide hydrocoride); Salix Pharmaceuticals; For the treatment of gastroesophageal reflux and diabetic gastroparesis, Approved September of 2009 Onglyza (saxagliptin); Bristol-Myers Squibb; For the treatment of type 2 diabetes mellitus, Approved July 2009 Onsolis (fentanyl buccal); Bio Delivery Sciences; For the management of breakthrough cancer pain, Approved July 2009 Pennsaid (diclofenac sodium topical solution); Nuvo Research; For the treatment of osteoarthritis of the knee, Approved November 2009 Sabril (vabatrin); Lundbeck; For the treatment of infantile spasms and complex partial seizures, Approved August 2009 Saphris (asenapine); Schering-Plough; For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009 Simponi (golimumab); Centocor Ortho Biotech; For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009 Stelara (ustekinumab); Janssen Biotech; For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease, Approved September 2009 Tyvaso (treprostinil); United Therapeutics; For the treatment of pulmonary arterial hypertension, Approved July 2009 Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009 Votrient (pazopanib); Glaxo Smith Kline; For the treatment of renal cell carcinoma, Approved October of 2009 Zipsor (diclofenac potassium); Xanodyne Pharmaceuticals; For the treatment of mild to moderate acute pain, Approved June 2009 Alvesco (ciclesonide); Nycomed; For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents, Approved January 2008 Aptivus (tipranavir); Boehringer Ingelheim; For the treatment of HIV, Approved June 2008 Banzel (rufinamide); Elan Pharmaceuticals; For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008 Cimzia (certolizumab pegol); UCB; For the treatment of Crohn’s disease, Approved April 2008 Cleviprex (clevidipine); The Medicines Company; For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008 Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008 Intelence (etravirine); Tibotec; For the treatment of HIV-1, Approved January 2008 Stavzor (valproic acid delayed release); Banner Pharmacaps; For the treatment of bipolar manic disorder, seizures and mraine headaches, Approved July 2008 Tysabri (natalizumab); Biogen IDEC; For the maintenance treatment of moderate to severe Crohn’s disease, Approved January 2008 Vimpat (lacosamide); Schwarz Pharma; For the treatment of partial-onset seizures in adults with epilepsy, Approved October 2008 Welchol (colesevelam hydrocoride); Daiichi Sankyo; For the improvement of glycemic control in adults with type 2 diabetes mellitus, Approved January 2008 Amrix (cyclobenzaprine hydrocoride extended release); Cephalon; For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007 Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo; For the treatment of hypertension, Approved September 2007 Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007 Evamist (estradiol); Vivus; For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007 Evista (raloxifene hydrocoride); Eli Lilly; For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007 Exelon (rivastmine tartrate); Novartis; For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007 Hycain (topotecan hydrocoride); Glaxo Smith Kline; For the treatment of small cell lung cancer, Approved October 2007 Isentress (raltegravir); Merck; For the treatment of HIV-1, Approved October 2007 Ixempra (ixabepilone); Bristol-Myers Squibb; For the treatment of breast cancer, Approved October 2007 Letairis (ambrisentan); Gilead; For the treatment of pulmonary arterial hypertension, Approved June 2007 Neupro (rototine); Schwarz Pharma; For the treatment of Parkinson's disease, Approved May 2007 Reclast (zoledronic acid); Novartis; For the treatment of postmenopausal osteoporosis, Approved August 2007 Renvela (sevelamer carbonate); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved October 2007 Selzentry (maraviroc); Pfizer; For the treatment of CCR5-tropic HIV-1, Approved August 2007 Soliris (eculizumab); Alexion; For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007 Tekturna (aliskiren); Novartis; For the treatment of hypertension, Approved March 2007 Torisel (temsirolimus); Wyeth; For the treatment of renal cell carcinoma, Approved May 2007 Tykerb (lapatinib); Glaxo Smith Kline; For the treatment of breast cancer, Approved March 2007 Vyvanse (Lisdexamfetamine Dimesylate); New River; For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007 Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006 Elestrin (estradiol gel); Bio Sante; For the treatment of vasomotor symptoms associated with menopause, Approved December 2006 Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006 Januvia (sitagliptin phosphate); Merck; For the treatment of type II diabetes, Approved October 2006 Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006 Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006 Ranexa (ranolazine); CV Therapeutics; For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006 Vectibix (panitumumab); Amgen; For the treatment of colorectal cancer, Approved September 2006 Verdeso (desonide); Connetics Corporation; For the treatment of atopic dermatitis, Approved September 2006 Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the treatment of alcohol dependence, Approved April 2006 ACTOplus met (pioglitazone hydrocoride and metformin hydrocoride); Takeda; For the treatment of type 2 diabetes, Approved August of 2005 Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005 Bi Dil (isosorbide dinitrate/hydralazine hydrocoride); Nitro Med; For the treatment of heart failure in black patients, Approved June, 2005 Boniva (ibandronate); Roche / Glaxo Smith Kline; For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005 Byetta (exenatide); Amylin/Eli Lilly; For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005 Nexavar (sorafenib); Bayer/Onyx; For the Treatment of Renal Cell Carcinoma, Approved December 2005 Orencia (abatacept); Bristol-Myers Squibb; For the Treatment of Rheumatoid Arthritis, Approved December 2005 Symlin (pramlintide); Amylin Pharmaceuticals; For the treatment of type I and type II diabetes, Approved March 2005 Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec; For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: s BLA Apokyn (apomorphine hydrocoride); Mylan Laboratories; For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinson’s disease, Approved April, 2004 Avastin (bevacizumab); Genentech; For the treatment of metastatic carcinoma of the colon or rectum, Approved February 2004 Caduet (amlodipine/atorvastatin); Pfizer; For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004 Campral (acamprosate calcium); Forest Laboratories; For the treatment of alcohol dependence and the maintenance of alcohol abstinence, Approved August, 2004 Cymbalta (duloxetine); Eli Lilly; For the treatment of major depressive disorder, Approved August 2004 Erbitux (cetuximab); Imclone, Bristol-Myers Squibb; For the treatment of EGFR-expressing, metastatic colorectal cancer, Approved February 2004 Estro Gel (estradiol gel 0.06%); Solvay Pharmaceuticals; For the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, Approved April 2004 Lyrica (pregabalin); Pfizer; For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, Approved December 2004 Spiriva Handi Haler (tiotropium bromide); Boehringer Ingelheim; For the treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved February 2004 Tarceva (erlotinib, OSI 774); Genentech, OSI Pharmaceuticals; For the treatment of advanced refractory metastatic non-small cell lung cancer, Approved November, 2004 Vioxx (rofecoxib); Merck; For the treatment of rheumatoid arthritis, Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004 Amevive (alefacept); Biogen IDEC; For moderate to severe chronic plaque psoriasis., Approved January 2003 Cialis (tadalafil); Eli Lilly; Oral agent for the treatment for erectile dysfunction, Approved December 2003 Finacea (azelaic acid) Gel, 15%; Berlex Laboratories; Gel formulation for the treatment of rosacea., January 2003 Fuzeon (enfuvirtide); Trimeris, Roche; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003 Iressa (gefitinib); Astra Zeneca; For the second-line treatment of non-small-cell lung cancer, Approved May 2003 Levitra (vardenafil); Bayer, Glaxo Smith Kline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003 Lexiva (fosamprenavir calcium); Glaxo Smith Kline; For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003 Namenda (memantine HCl); Forest Laboratories; For the treatment of moderate to severe dementia of the Alzheimer’s type., Approved October 2003 Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals; For treatment of advanced prostate cancer, Approved December 2003 Premarin (conjugated estrogens); Wyeth; For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003 Reyataz (atazanavir sulfate); Bristol-Myers Squibb; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003 Uro Xatral (alfuzosin HCl extended-release tablets); Sanofi-aventis; For the treatment of of the sns and symptoms of benn prostatic hyperplasia, Approved June 2003 Xolair (omalizumab); Genentech; For the treatment of asthma, Approved June 2003 Aciphex (rabeprazole sodium); Elan Pharmaceuticals; For the treatment of symptomatic gastroesophageal reflux disease, Approved February 2002 Alora; Watson Pharmaceuticals; Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms, Approved April 2002 Avandamet (roslitazone maleate and metformin HCl); Glaxo Smith Kline; For improvement of glycemic control in type 2 diabetes patients, Approved October 2002 Avinza (morphine sulfate); Elan Pharmaceuticals; Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002 Benicar; Daiichi Sankyo; Oral tablet for the treatment of hypertension, Approved April 2002 Botox Cosmetic (botulinum toxin type A); Allergan; For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002 Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals; Human-derived follicle-stimulating hormone (h FSH) for use in ovulation induction for the treatment of infertility., Approved May 2002 Elard (leuprolide acetate); Atrix Laboratories; For the palliative treatment of advanced prostate cancer, Approved January 2002 Enbrel (etanercept); Immunex; For the treatment of psoriatic arthritis, Approved January 2002 Faslodex (fulvestrant); Astra Zeneca; For the treatment of hormone receptor positive metastatic breast cancer, Approved April 2002 Forteo (teriparatide); Eli Lilly; For the treatment of Osteoporosis in postmenopausal women and men who are at hh risk for a fracture., December 2002 Humira (adalimumab); Abbott Laboratories; For the treatment of moderately to severely active rheumatoid arthritis, Approved December 2002 Inspra (eplerenone tablets); Pharmacia & Upjohn; Oral tablets for the treatment of hh blood pressure., Approved September 2002 Lexapro (escitalopram oxalate); Forest Laboratories; An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder, Approved August 2002 Metaglip (glipizide/metformin HCl); Bristol-Myers Squibb; Oral tablets for the treatment of type 2 diabetes., Approved October 2002 Paxil CR (paroxetine hydrocoride); Glaxo Smith Kline; Oral tablet for the treatment of depression and panic disorder, Approved February 2002 Qvar (beclomethasone dipropionate); Ivax; For the treatment of asthma, Approved May 2002 Rebif (interferon beta-1a); Serono Laboratories; Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis, Approved March 2002 Relpax (eletriptan hydrobromide); Pfizer; For the acute treatment of mraine headaches, Approved December 2002 Remicade (infliximab); Centocor Ortho Biotech; Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002 Remodulin (treprostinil); United Therapeutics; For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002 Ritalin LA (methylphenidate HCl); Novartis; Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002 Strattera (atomoxetine HCl); Eli Lilly; For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002 Sustiva; Bristol-Myers Squibb; Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002 Vfend (voriconazole); Pfizer; For the treatment of fungal infections, Approved May 2002 Zelnorm (tegaserod maleate) Tablets; Novartis; For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation, Approved July 2002 Adderall XR; Shire Pharmaceuticals; Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001 Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals; For the treatment of cholesterol disorders, Approved December 2001 Avelox I. (moxifloxacin hydrocoride); Bayer; Injectable antibacterial agent for adults with susceptible strains of bacterial infections, Approved November 2001 Axert (almotriptan malate) tablets; Pharmacia & Upjohn; For the treatment of mraine attacks, Approved May 2001 Bayer Extra Strength Asprin; Bayer; Oral treatment for mild to moderate mraine pain, Approved October 2001 Bextra; Pharmacia, Pfizer; Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001 Cancidas; Merck; Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001 Diovan (valsartan); Novartis; Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets) Duo Neb (albuterol sulfate and ipratropium bromide); Dey Laboratories; For the treatment of bronchospasm associated with COPD, Approved March 2001 Dutasteride; Glaxo Smith Kline; For the treatment of symptomatic benn prostatic hyperplasia, Approved November 2001 Elidel; Novartis; Topical cream for the treatment of atopic dermatitis, Approved December 2001 Entocort EC (budesonide); Astra Zeneca; Capsules for the treatment of mild-to-moderate, active Crohn's disease, Approved October 2001 Estrostep (norethindrone acetate and ethinyl estradiol); Pfizer; For the treatment of moderate acne vulgaris, Approved July 2001 Femara (letrozole); Novartis; First-line treatment of postmenopausal women with loy advanced or metastatic breast cancer, Approved January 2001 Finevin; Berlex Laboratories; Topical cream for the treatment of mild to moderate inflammatory acne vulgaris, Approved May 2001 Focalin (dexmethylphenidate HCl); Celgene; For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001 Foradil Aerolizer (formoterol fumarate inhalation powder); Novartis; Bronchodilator for COPD, asthma and bronchospasm, Approved February 2001 (asthma, bronchospasm); September 2001 (COPD) Frova (frovatriptan succinate); Elan Pharmaceuticals; Tablets for the acute treatment of mraine attacks, Approved November 2001 Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001 Kineret; Amgen; Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001 Lamisil Solution, 1%; Novartis; Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001 Luman (bimatoprost ophthalmic solution); Allergan; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001 Metadate CD; Celltech Pharmaceuticals; Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001 Nexium (esomeprazole magnesium); Astra Zeneca; For the eradication of Helicobacter pylori, the healing of erosive esophagitis, and the treatment of symptomatic GERD, Approved February 2001 Novolog Mix 70/30; Novo isk; Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes, Approved November 2001 Protonix (pantoprazole sodium) Intravenous Formulation; Wyeth; For the short-term treatment of gastroesophageal reflux disease, Approved March 2001 Prozac Weekly (fluoxetine HCl); Eli Lilly; For the treatment of depression, Approved February 2001 Remeron Sol Tab (mirtazapine); Organon; Orally disintegrating tablet for the treatment of depression, Approved January 2001 Remicade (infliximab); Centocor Ortho Biotech; For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001 Reminyl (galantamine hydrobromide); Janssen Pharmaceuticals; For the treatment of mild to moderate dementia of the Alzheimer's type, Approved February 2001 Spectracef; TAP Pharmaceuticals; Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001 Supartz; Smith & Nephew Orthopaedics; Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001 Tavist (clemastine fumarate); Novartis; Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001 Teveten (eprosartan mesylate plus hydrocorothiazide); Unimed Pharmaceuticals; Tablets for the treatment of hypertension, Approved November 2001 Tracleer (bosentan); Actelion; For the treatment of pulmonary arterial hypertension, Approved November 2001 Travatan (travoprost ophthalmic solution); Alcon; For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001 Trelstar LA (triptorelin pamoate); Debiopharm; Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001 Tricor (fenofibrate); Abbott Laboratories; For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertrlyceridemia, Approved September 2001 Ultracet (acetaminophen and tramadol HCl); Ortho-Mc Neil Pharmaceutical; For the short-term management of acute pain, Approved August 2001 Valcyte (valganciclovir HCl); Roche; For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001 Ventolin HFA (albuterol sulfate inhalation aerosol); Glaxo Smith Kline; For the treatment or prevention of bronchospasm, Approved April 2001 Viread (tenofovir disoproxil fumarate); Gilead; Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001 Zom (zolmitriptan); Astra Zeneca; Orally disintegrating tablet for the treatment of acute mraine in adults, Approved February 2001 Activella (Estradiol/Norethindrone Acetate) Tablets; Novo isk; Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000 Atacand (candesartan cilexetil); Astra Zeneca; For the treatment of hypertension, Approved September 2000 Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel); Dermik Laboratories; For the topical treatment of acne vulgaris, Approved November 2000 Betaxon; Alcon; For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension, Approved February 2000 Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories; For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000 Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000 Children's Motrin Cold; Mc Neil Consumer Products; For temporary relief of the common cold, Approved August 2000 Clindamycin phosphate topical gel; Target Research Associates; For once a day treatment of acne vulgaris, Approved November 2000 Colazal (balsalazide disodium); Salix Pharmaceuticals; Mild to moderately active ulcerative colitis, Approved July 2000 Concerta; Alza; For the treatment of Attention Deficit Hyperactivity Disorder, Approved August 2000 Depakote ER (divalproex sodium); Abbott Laboratories; For the prophylaxis (prevention) of mraine headaches in adults, Approved August 2000 Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories; For the reduction of hh blood pressure, Approved January 2000 Exelon (rivastmine tartrate); Novartis; Indicated for the treatment of mild to moderate dementia of the Alzheimer's type, Approved April 2000 Kaletra Capsules and Oral Solution; Abbott Laboratories; For the treatment of HIV-1 infection, Approved September 2000 Lamisil (terbinafine hydrocoride) Solution, 1%; Novartis; For the treatment of atete's foot, jock itch and ringworm, Approved March 2000 Lantus (insulin glargine [r DNA orin] injection); Sanofi-aventis; For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000 Lantus (insulin glargine [r DNA orin] injection); Sanofi-aventis; For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000 Lescol XL (fluvastatin sodium) tablet, extended release; Novartis; For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000 Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough; For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000 Lotronex (alosetron HCL) Tablets; Glaxo Smith Kline; Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS, Approved February 2000 Micardis HCT (telmisartan and hydrocorothiazide); Boehringer Ingelheim; For the treatment of hypertension, Approved November 2000 Mobic (meloxicam) Tablets; Boehringer Ingelheim; For relief of the sns and symptoms of osteoarthritis, Approved April 2000 Neurontin (gabapentin) oral solution; Parke-Davis; Treatment of partial seizures in adults with epilepsy, Approved March 2000 Neurontin (gabapentin) oral solution; Parke-Davis; For the treatment of partial seizures in pediatric patients three years of age and older, Approved October 2000 Nitrostat (nitroglycerin) Tablets; Parke-Davis; For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000 Novantrone (mitoxantrone hydrocoride); Immunex; For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis, Approved October 2000 Novo Log (insulin aspart); Novo isk; An insulin analogue for the treatment of diabetes mellitus., Approved June 2000 Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories; For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000 Pepcid Complete; Merck; For use in the relief of heartburn associated with acid indestion and sour stomach, Approved October 2000 Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth; For treatment of erosive esophagitis, Approved February 2000 Protopic (tacrolimus) ointment; Fujisawa Healthcare; For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis, Approved December 2000 Renagel (sevelamer hydrocoride); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000 Rescula (unoprostone isopropyl ophthalmic solution) 0.15%; Ciba Vision; For the treatment of open-angle glaucoma or ocular hypertension, Approved August 2000 Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates; For the palliative treatment of advanced prostate cancer, Approved June 2000 Trileptal (oxcarbazepine) Tablets; Novartis; Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000 Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; Glaxo Smith Kline; For the treatment of HIV-1 infection, Approved November 2000 Venofer (iron sucrose injection); Luitpold Pharmaceuticals; For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000 Viadur (leuprolide acetate implant); Alza; For pain relief in men with advanced prostate cancer, Approved March 2000 Vivelle (estradiol transdermal system); Novartis; For the prevention of postmenopausal osteoporosis, Approved August 2000 Zonegran (zonisamide) Capsules; Dainippon Pharmaceutical; Adjunctive therapy for treatment of partial seizures in adults with epilepsy, Approved March 2000 Accolate; Astra Zeneca; zafirlukast, 10 mg and 20 mg tablets., Approved September 1999 Aggrenox; Boehringer Ingelheim; Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999 Aromasin Tablets; Pharmacia & Upjohn; Exemestane Tablets, 25 mg, October 21, 1999 Coan; Novartis; 200mg entacapone tablets, October 19, 1999 Ellence; Pharmacia & Upjohn; epirubicin hydrocoride, Approved September 1999 Evista (raloxifene hydrocoride); Eli Lilly; Osteoporosis treatment, Approved September 1999 Femhrt Tablets; Parke-Davis; Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999 Keppra; UCB; Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy, Approved November 1999 Ortho-Prefest; Ortho-Mc Neil Pharmaceutical, RW Johnson; 17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999 Synercid I. Uceris budesonide; Santarus; For the treatment of ulcerative colitis, Approved. FLOMAX; Boehringer Ingelheim; Treatment for benn prostatic hypertrophy.

Clinical Pharmacology - SlideShare Ulcerative colitis can cause pain, fatue, anemia, and serious bowel symptoms. Jun 6, 2010. Drugs on GIT 1 – peptic ulcer Drugs on GIT 2 – motility and secretions. ulcerative colitis • Gallstone Diarrhoea • Diphenoxylate Lomotil, Kaolin, Side. Postural Hypotension Terazosin, Tamsulosin Flomax, Bethanidine.

Welcome to PDR+ for Patients - PDR. Net Nonspecific ulcerative colitis is a chronic inflammatory disease of the intestine, which develops starting from the rectum. Welcome to PDR+ for Patients. Search or browse the over 2,300 drug guides by drug name to view trusted, reliable drug guides written for the patient and available on.

Find Your Medication Rx Outreach Camera del bambino, iene personale, abbliamento. La camera del bambino E’ dimostrato che gli acari della polvere domestica, (micro-organismi invisibili ad occhio nudo presenti nella polvere di quasi tutte le case), possono essere responsabili, in parte più o meno accentuata, dell’insorgenza, mantenimento ed evoluzione verso l’asma della dermatite atopica; una particolare attenzione, pertanto, va posta all’ambiente in cui il bambino trascorre buona parte della giornata: la sua cameretta. Ulcerative Colitis, Balsalazide Disodium Capsule, Colazal® * / Giazo®, 750mg, for up to 90. Prostate, Tamsulosin Capsule, Flomax® *, 0.4mg, , .

What is Ulcerative Colitis Symptoms, Treatment & Causes Buy Estrace (Estradiol) Online In stock, delivery on request! A form of estrogen, Generic Estrace is used for compensating for the deficit of this vitally important female sex hormone that is normally produced by a female body. Symptoms of ulcerative colitis are generally frequent bowel movements, lower abdominal cramping, fever, and weht loss.

Inflammatory Bowel Diseases Crohns & Ulcerative Colitis Our Cell Therapy Center offers advanced patented methods of stem cell treatment for different diseases and conditions. Physiology lecture on the pathophysiology of inflammatory disease. Provides a comparison and contrast between ulcerative colitis & crohn's disease.

Multiple Sclerosis & IBD Linked in New Study The fetal stem cells we use have the hhest potential for differentiation into other cell types and are not rejected by the recipient’s body read more... Oct 6, 2014. association between MS and inflammatory bowel disease IBD, with increased incidence of Crohn's disease CD and ulcerative colitis UC.

Ulcerative Colitis There is no clinical or scientific evidence that supports the theory that a specialized diet may cause or benefit individuals with ulcerative colitis (UC). Ulcerative Colitis is a disease that is characterised by inflammation and micro-ulcers in the superficial layers of the large intestine.

Ulcerative Colitis Symptoms, Diet, Treatment & It is possible that the main title of the report Ulcerative Colitis is not the name you expected. Read about ulcerative colitis causes, and symptoms such as diarrhea, abdominal pain, rectal bleeding, rectal pain, urgency to defecate, or painful bowel movements.


Flomax ulcerative colitis:

Rating: 97 / 100

Overall: 91 Rates